TriSalus Life Sciences (TLSI) Cash from Financing Activities (2022 - 2026)

TriSalus Life Sciences has reported Cash from Financing Activities for 5 years, with the latest figure at $42.4 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Financing Activities rose 337.5% year-over-year to $42.4 million; the trailing twelve-month figure through Mar 2026 stood at $63.5 million (up 42.62% YoY), and the FY2025 full-year result was $30.8 million, down 18.91% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at $42.4 million, up from $277000.0 in the prior quarter.
• The five-year high for Cash from Financing Activities was $42.4 million in Q1 2026, with the low at $43000.0 in Q4 2023.
• Historically, Cash from Financing Activities has averaged $10.5 million across 5 years, with a median of $5.9 million in 2022.
• Annual changes were most pronounced in 2023 — Cash from Financing Activities slumped 99.27% — and 2024, when it surged 6862.79%.
• TriSalus Life Sciences' Cash from Financing Activities stood at $5.9 million in 2022, then tumbled by 99.27% to $43000.0 in 2023, then surged by 6862.79% to $3.0 million in 2024, then sank by 90.75% to $277000.0 in 2025, then surged by 15201.44% to $42.4 million in 2026.
• The last three Cash from Financing Activities figures came in at $42.4 million (Q1 2026), $277000.0 (Q4 2025), and $82000.0 (Q3 2025), per Business Quant data.